Foresight Acquisition Corp.: directors' dealings · United States · SEC (Form 4)

About Foresight Acquisition Corp.

Foresight Acquisition Corp. (ticker FORE) was a U.S.-listed special purpose acquisition company, or SPAC, associated with the NASDAQ market before completing its business combination with P3 Health Partners. For investors, the key point is that Foresight was not a traditional operating company with its own product line; it was created to raise capital and identify a merger target. SEC filings show that Foresight was incorporated in Delaware on August 20, 2020, with the purpose of completing a business combination, such as a merger or asset acquisition, with one or more operating businesses. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1832511/000162828025015305/piii-20241231.htm?utm_source=openai)) Following the transaction, the listed vehicle became P3 Health Partners Inc., while the Foresight name remained important mainly for corporate-history and filing-reference purposes. The merger was completed on December 3, 2021, and the company subsequently adopted the P3 Health Partners name. This means that any analysis of FORE should be understood through the lens of the underlying healthcare platform that Foresight brought public, rather than as a standalone operating business. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1832511/000162828025015305/piii-20241231.htm?utm_source=openai)) The operating business connected to the Foresight transaction is P3 Health Partners, described in public disclosures as a patient-centered and physician-led population health management company. In practical terms, that means the business model is centered on healthcare management services rather than pharmaceuticals or medical devices. Its core lines of activity include population health management, care coordination, and operational support for physicians and clinicians, with an emphasis on value-based care dynamics. This positioning places the company in a competitive segment alongside managed-care operators, healthcare enablement platforms, and other services businesses focused on improving outcomes and controlling costs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1832511/000119312521313425/d207774ddefa14a.htm?utm_source=openai)) Geographically, the public record points to a primarily United States footprint. The company is a U.S. entity, and disclosures reference expansion in California’s Central Valley, indicating a meaningful presence in that state. For European investors, the practical takeaway is that the business is exposed to the U.S. healthcare reimbursement environment, U.S. regulatory standards, and the listing requirements of a U.S. exchange, specifically NASDAQ during the relevant Foresight period. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1832511/000119312521313425/d207774ddefa14a.htm?utm_source=openai)) Recent material milestones center on the merger itself and the corporate restructuring that followed. The SEC record and investor materials consistently reference the original Foresight SPAC structure, the closing of the business combination, and the subsequent name change. That history remains relevant when reviewing SEC Form 4 insider transactions, because filings may still refer to legacy entity names, sponsor holdings, and securities created in connection with the SPAC process. In short, Foresight Acquisition Corp. is best viewed as the public-market gateway that helped launch a healthcare platform, rather than as a classic operating company with its own standalone products. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1832511/000162828025015305/piii-20241231.htm?utm_source=openai))